Teva, APP enter agreement for launch of generic Gemzar

Links shared publicly online about this topic.

551
total visits

Teva, APP enter agreement for launch of generic Gemzar

Teva Pharmaceutical Industries Ltd. and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar®, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies.

View full resource at news-medical.net

Tags: Cancer Medication, Pharma, Health Insurance, Medicare, Gemzar, Teva Pharmaceutical Industries, News